Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma

Ching‐Jung Lin, Ching-Jung Lin, Teh-Fu Hsu, Teh‐Fu Hsu, Yen-Hou Chang, Ben-Shian Huang, Ling-Yu Jiang, Peng‐Hui Wang, Peng-Hui Wang, Yi-Jen Chen, Yi‐Jen Chen
Taiwanese journal of obstetrics & gynecology · 2018 · vol. 57(1) , pp. 47–51 · doi:10.1016/j.tjog.2017.12.036 · PMID:29458902 · W2792505068
article OA: diamond CC0 ⤵ 16 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

OBJECTIVE: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing the recurrence of postoperative adenomyosis-related symptoms. MATERIALS AND METHODS: From January 2005 through December 2014, a retrospective study including 133 patients with symptomatic adenomyosis undergoing conservative uterine-sparing surgery followed by gonadotropin-releasing hormone agonist treatment was conducted. We excluded the 18 patients who did not meet the inclusion criteria. The patients of intervention group (n = 54) received a levonorgestrel-releasing intrauterine system (LNG-IUS), which was inserted after surgery. The patients without LNG-IUS insertion were enrolled in the control group (n = 61). The primary outcome was improvement of adenomyosis-related dysmenorrhea, which was evaluated by the visual analog scale (VAS) and by hemoglobin (Hgb) and CA-125 levels. RESULTS: Over a 12-month follow-up, the intervention group exhibited a greater reduction in dysmenorrhea as assessed with a VAS score (mean ± SD: 6.5 ± 2.5 vs 4.1 ± 3.6, p = 0.001) and a greater elevation in the Hgb level (2.1 ± 1.9 vs 1.0 ± 1.7, p = 0.008) than the control group. At the end of the 24-month follow-up period, the intervention group also exhibited a greater reduction in dysmenorrhea as assessed with a VAS score (mean ± SD 6.1 ± 2.7 vs 3.7 ± 3.7, p = 0.002) and a greater elevation in the Hgb level (1.9 ± 2.1 vs 0.7 ± 1.8, p = 0.022) than the control group. The CA-125 level was significantly lower in the intervention group during the postoperative follow up (12th month follow-up, intervention vs control, 24.5 ± 28.8 vs 50.1 ± 44.0, p = 0.005; 24th month follow-up, 28.6 ± 26.2 vs 75.4 ± 68.5, p = 0.002). CONCLUSION: The maintenance therapy of LNG-IUS is effective and well accepted for long-term therapy after conservative surgery for patients with adenomyosis.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

mesh:D004412adenomyosisdysmenorrhea

MeSH descriptors

Adenomyoma Intrauterine Devices, Medicated Levonorgestrel Uterine Neoplasms Adenomyoma Adenomyoma Adult CA-125 Antigen CA-125 Antigen Dysmenorrhea Dysmenorrhea Female Follow-Up Studies Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Hemoglobins Hemoglobins Humans Intrauterine Devices, Medicated Levonorgestrel

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (16)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:55.107525+00:00
License: CC0 · commercial use OK